A world where every patient diagnosed with any cancer will quickly have access to a data-driven, clinically proven approach to treatment. Download the ARC Vision Statement here.
The fractured landscape of rare cancer research must transform into a strategic alliance between rare cancer stakeholders. ARC is therefore creating a strategic, coordinated national alliance capable of solving the key challenges that impede innovation in rare cancer treatments.
In the race for better cancer treatments, rare cancer patients have been left behind despite comprising 25% of cancer patients because institutions across the discovery, development, and care delivery ecosystem currently lack infrastructure for rare cancers. ARC is positioned to rapidly build novel infrastructure that allows access to patient tissue and preclinical models to deliver data-driven approaches in rare cancers without the friction of large-scale change management.
5-year survival rates for people diagnosed with rare cancers are stagnant. 1 in 4 cancer diagnoses in the U.S. and every type of pediatric cancer are rare cancers. While extensive research investments over the past 25 years have led to considerable progress in overall outcomes for “common cancers” and in some select cases, durable remissions, rare cancer patients have not meaningfully shared in these improvements.
Every patient deserves the right to understand and make data-informed choices in partnership with a medical and scientific community that encourages patient voices and active participation.
New transformative science is poised to deliver life-saving treatment and even cures for some cancer patients. Technological innovations have made data-driven approaches for rare cancer possible and together, the rare cancer community is now able to seize such a moment. The ability to perform distributed research and clinical science to overcome challenges of geographic dispersion are finally addressable thanks to the widespread adoption of telecommunication platforms and the digital transformation of many sectors.
Organizations that fully seize this opportunity, at the needed scale, will become world leaders ushering in the full promise of data-driven therapy for all cancer patients. Further, the rare cancer community is uniquely positioned to change the R&D ecosystem for all. With an organized, systematic approach we can ensure these emerging technologies are focused on and optimized for rare cancers, ensuring a new era of hope for rare cancer patients everywhere. Download the ARC Vision Statement
Alliance for Rare Cancers I Jedi Rare Cancer Foundation
P.O. Box 683501, Park City, Utah 84068
The Alliance for Rare Cancers is a fiscally sponsored program of the Jedi Rare Cancer Foundation, a 501(c)(3) nonprofit organization, accepting tax-deductible donations from individuals, corporations, family-advised funds, and foundations. Federal Tax ID 86-2610819. All donations are tax deductible as allowed by law.
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.